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of a brief motivational intervention on problem
drug and alcohol use in adult mental health
inpatient units: study protocol for a randomized
controlled trial
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Background: Substance misuse in those with severe mental health problems is common and associated with poor
engagement in treatment and treatment outcomes. Up to 44% of those admitted into psychiatric inpatient facilities
have coexisting substance-misuse problems. However, this is not routinely addressed as part of their treatment plan.
A mental health admission may present a window of opportunity for inpatients to reevaluate the impact of their
substance use. This study will aim to evaluate the effectiveness of a targeted brief motivational intervention in
improving engagement in treatment and to assess how feasible and acceptable this intervention is to inpatients
and staff as a routine intervention.
Methods/Design: This randomized controlled trial will use concealed randomization; blind, independent
assessment of outcome at 3 months; characterization of refusers and dropouts; and be analyzed according to the
intention-to-treat principle. After baseline assessments, eligible participants will be randomized either to the Brief
Integrated Motivational Intervention plus Treatment As Usual, or Treatment as Usual alone. Eligible participants
will be those who are new admissions; >18 years; ICD-10 diagnosis of -schizophrenia or related disorder, bipolar
affective disorder, recurrent depressive disorder, and DSM-IV diagnosis of substance abuse or dependence over the
last 3 months. The primary outcome is engagement in treatment for substance misuse, and secondary outcomes
include readiness to change substance misuse together with a cost-effectiveness analysis. Qualitative interviews with
staff and participants will assess the acceptability of the intervention.
Discussion: This pilot randomized trial will provide the first robust evidence base for inpatient care of people with
severe mental health problems and co-morbid substance misuse and provide the groundwork for confirmatory
trials to evaluate a potentially feasible, cost-effective, and easy-to-implement treatment option that may be readily
integrated into standard inpatient and community-based care.
Trial registration: ISRCTN43548483 Date of ISRCTN assignation: 4/17/2014.
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Substance misuse in mental health-admission units
It is now well recognized that substance misuse in those
with severe mental health problems is common [1-4], as-
sociated with poor engagement in treatment and treat-
ment outcomes [5-7] and low motivation to change drug
and alcohol use [8-10]. However, poor treatment engage-
ment is a barrier for change and good treatment out-
comes [6,10-12]. In addition, substance misuse among
this population is also associated with increased psychi-
atric hospital admissions and is found to affect inpatient
stays negatively [13]. In the UK, 22% to 44% of those ad-
mitted into psychiatric inpatient facilities for mental
health problems have been found also to have coexisting
alcohol or drug problems [13]. Policy guidance has pointed
to the need to train staff to improve routine assessment
and treatment of substance misuse as part of the clinical-
management strategy of a psychiatric admission [13].
Nonetheless, this has continued to be highlighted as a
significant gap in service provision, and outcomes for
this group remain poor [14,15].
As acute symptoms of mental ill health decline, this
can be characterized as a time of contemplation and a
window of increased awareness and insight into the fac-
tors that contributed to becoming mentally unwell and
or being admitted into hospital [16,17]. However, such
increased insight may result in increased emotional dis-
tress, and research has shown that after discharge, some
individuals may “seal over” the experience, in an attempt
to reduce emotional distress [18]. That is, they may deny
or minimize recent mental health symptoms or experi-
ences and precipitating factors, and as a result, lose aware-
ness of the triggers for becoming unwell [18].
Sealing over the experience of relapse was found to
predict low engagement with mental health services 6
months after discharge for psychiatric inpatients [18].
However, engagement in treatment is found to be a key
in improving treatment outcomes [10,19]. Hence, we
propose that a targeted brief motivational intervention
could use this “window of opportunity” to increase the
focus on the role drug and alcohol use may have played
in the exacerbation of mental health symptoms and ac-
tively link participants with substance-misuse treatment
routinely integrated within community mental health
teams. Hence a mental health admission may well repre-
sent a window of opportunity for individuals who misuse
substances to be offered treatment to help them reevalu-
ate their drug/alcohol use and become aware of the
negative impact of it on their mental health [13,14,16].
Inpatient policy guidance recommends that staff be
trained in simple approaches to improve motivation and
encourage change in substance use [13]. A recent Cochrane
review [20] indicated mixed findings in trials of the effect-
iveness of long-term psychological interventions withpsychosis and substance misuse, potentially because of
variations in methodology and samples. However, it points
to the need to evaluate brief interventions, such as motiv-
ational interviewing, to enable service providers to identify
a cost-effective and easy-to-implement component that
may be quickly integrated into standard care. Brief
motivational interventions have demonstrated good re-
sults across the range of substances, often equivalent to
longer-term interventions, across a range of populations
[21-25]. Motivational interventions seek to change views
about alcohol/drug use or drug/drinking behavior. This
would be seen as an initial step in promoting long-term
changes in behavior.
The evidence base regarding the use of motivational-
based interventions with this client group is encouraging
[10,26-29]. However, the evidence suggests that brief inter-
ventions be provided within the context of a comprehensive
package of ongoing integrated treatment. Thus the aim of
this trial is to target drug and alcohol misuse among inpa-
tients with severe mental health problems to determine
whether offering a Brief Integrated Motivational Interven-
tion (MI) to inpatients will lead to greater engagement in
substance-misuse treatment and motivation to change sub-
stance misuse in community services after discharge.
Hypotheses
The primary hypothesis to be evaluated is whether en-
gagement in treatment for substance misuse can be sig-
nificantly improved by the MI provided in the context of
treatment as usual (TAU). The secondary hypotheses are
that those receiving the MI will show greater readiness
to change substance-use behavior than those receiving
treatment as usual and that the MI + TAU will be more
cost-effective than the TAU.
Method/Design
The trial is funded by the National Institute for Health
Research-Research for Patient Benefit and has received
ethical approval from the West Midlands–The Black
Country National Research Ethics Committee (REC refer-
ence: 12/WM/0369). It is a single (rater) blind, intention-
to-treat analysis, prospective randomized trial to assess
the feasibility and impact of a brief motivational inter-
vention for drug and alcohol misuse in mental health ad-
mission units. The trial uses concealed randomization;
blind, independent assessment of outcome at 3 months;
characterization of refusers and dropouts; and analysis by
intention to treat. Participants consented and then ran-
domized on a 1:1 basis, to one of two experimental condi-
tions: MI in the context of Treatment As Usual or TAU.
Participants being recruited are adults aged 18 years or
older with schizophrenia, schizoaffective or delusional dis-
orders, bipolar affective disorders or recurrent depressive
disorder, users of community mental health services; new
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West Midlands within the acute phase of severe mental
health problems; who are also misusing substances (alcohol
and/or drugs). Participants are recruited from six inpatient
units, including 11 acute wards and three Psychiatric Inten-
sive Care Units (PICUs), which offer a total of 202 beds.
Recruitment to the trial began in April 2013 and is on-
going until July 2014. Follow-up assessments began in
May 2013 and will be completed by September 2014.
The intervention
The MI is offered in the context of TAU. The MI seeks
to encourage participants to engage in talking about
their substance use and its impact on their mental
health, the fundamental first step in the process of pro-
moting a readiness and willingness to change problem-
atic drug/alcohol use. The initial aim is twofold; first,
to increase awareness of the advantages and the disad-
vantages of continued substance misuse, and second, to
build awareness of the impact of substance use on mental
health.
The next stage encourages participants to contemplate
change and make a change plan, thereby making change
feel possible. Participants are provided with individually
tailored psychoeducational material about substances
and, between sessions, are also encouraged to access
websites offering information about alcohol (”Down your
Drink”) and drugs (”Talk to Frank”). Participants are of-
fered a Peer Mentor after the first week of the interven-
tion. The Peer Mentor will aim to show empathy and
understanding during a difficult time for the participants,
to share personal experiences, to offer an alternative out-
look on problematic substance use, and to provide some
support and solidarity.
The MI is based on specifically trained staff on the wards
working alongside staff from the specialist COMPASS
Programme team (a specialist “dual diagnosis” Trust-wide
service) [30]. Their aim is building good collaborative rela-
tionships with participants working toward a joint goal of
“keeping participants from returning to hospital”. The MI
takes place over a 2-week period for four to six sessions
for 15 to 30 minutes on each occasion. At the final session
of the 2-week intervention, the booster session is arranged
for a month.
The booster session is provided by a member of the
specialist COMPASS Programme Team and attended by
the participant’s Care Co-ordinator. It will seek to help
consolidate motivation and transfer the skills from the
MI to the community and to link participants actively
with substance-misuse treatment routinely integrated
within community mental health teams.
The structure of the MI attempts to map itself onto the
stage of recovery in acute psychosis in a targeted manner.
It targets the initial window of contemplation during theadmission and then is timed to coincide with just before
“sealing over” and disengagement [16,18] are predicted
to occur. The MI is delivered jointly by a staff member
on the unit and a member of the specialist COMPASS
Programme team [30], according to a therapy manual de-
signed for this purpose. Staff are trained and supervised in
the delivery of the MI by three of the Investigators. The
standard to which staff deliver the MI is regularly moni-
tored and assessed for fidelity and adherence.
Treatment as usual
Treatment as usual will be documented. It is mostly pro-
vided by nursing and medical staff on the mental health
admission units in line with inpatient trust policies, regu-
larly monitored by the UK Care Quality Commission. It
will primarily consist of assessment and monitoring men-
tal state, provision of medication, and stabilization of the
mental state.
Inclusion and exclusion criteria
Eligible participants are adults aged 18 or older with se-
vere mental health problems, who are service users of
community mental health services and have been admit-
ted to mental health inpatient units within the acute phase
of severe mental health problems and who are also misus-
ing substances (alcohol and/or drugs). They will have
an ICD-10 diagnosis of schizophrenia, schizoaffective or
delusional disorders (F20,22,23,25,28,29); bipolar affective
disorders (F31); recurrent depressive disorder without
psychotic symptoms (F33.2) (32), and be identified as
misusing alcohol and/or drugs over the past month, in
addition to a minimum score of 3 (abuse/dependent use
based on DSM-IV diagnostic criteria for substance-related
disorders) on the Clinicians Alcohol/Drugs Use rating
scale over the past 3 months [31]. They also must be
assessed by the Responsible Clinical Officer as having
capacity to consent, and have a Care Co-ordinator in a
Community Mental Heath Team. Participants who have
already been entered in the trial but are re-admitted to the
inpatient unit are not screened again but continue to be
treated as trial participants and monitored as per protocol.
Recruitment and randomization
Eligible participants are identified by Research Associates
in conjunction with Clinical Studies Officers (CSOs) from
the Mental Health Research Network, who review care
records. The Research Associates complete a screen-
ing measure with Care Co-ordinators to confirm eligi-
bility for the trial. The Research Associates then visit
eligible participants within 2 weeks of admission, once
the acute symptoms have been assessed as eased and
the inpatient is deemed able to provide informed con-
sent. Eligible participants are invited to take part and
asked to provide informed consent.
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been obtained, the researchers administer a battery of as-
sessments, and on completion, participants are randomly
allocated either to the MI group (in the context of TAU)
or the TAU group (the control group). At the end of the
baseline assessment session, the researchers schedule a
meeting with the participant for 2 weeks’ time, to complete
the posttreatment assessments. Just before the 3-month
data-collection point, the researchers contact the Care
Co-ordinator to schedule a meeting for the completion of
the 3-month follow-up assessment battery.
The trial uses independent central randomization by
using a concealed process via Email. Both researchers
are blind to participant treatment group allocation until
all baseline, posttreatment, and 3-month follow-up quanti-
tative assessments have been completed. Treatment allo-
cation is available to the researchers once the 3-month
data-collection point (primary outcome) has been com-
pleted. Participants in the MI group then complete the
qualitative interview.
Data also are collected regarding the total number of
participants admitted to the inpatient unit, the number
who use substances, and the number who are eligible and
consent to participate in the study.
Given the pragmatic design of the trial and the nature of
inpatient units, it is possible that some leakage of MI com-
ponents into TAU may occur through participants or staff.
Participants may inadvertently discuss or share information
about the MI, or inpatient staff trained to use the interven-
tion may provide parts of it to those participants in the
TAU arm. Any contamination bias will be limited by steps
taken by the trial team. A number of methods will be used
to reduce potential leakage. Participants will be informed of
the nature of the study during the consenting process and
asked not to share any information about the treatment
they receive. An important component of the training ses-
sions for Inpatient staff and Peer Mentors in the interven-
tion arm will involve education and awareness about the
importance of blinding and ensuring that only those allo-
cated to the MI receive the elements of the intervention.
This is also to be discussed during supervision sessions.
Measures
Primary outcome
Primary outcome will be engagement with substance-
misuse treatment while inpatients and with community
treatment services at 3-month follow-up, as reported
by Care Co-ordinators/primary clinician, by using the
Substance Abuse Treatment scale [8,31]. Engagement is
assessed by using the Substance Abuse Treatment Scale
(SATS), a widely used and standardized measure that uses
an eight-stage hierarchic motivational model of engage-
ment in substance-misuse treatment to assess the stage of
recovery from substance misuse.Care Coordinators are asked to categorize the level of
engagement in substance-misuse treatment on an 8-point
scale: the categories are pre-engagement, engagement, early
persuasion, late persuasion, early active treatment, late
active treatment, relapse prevention, and in remission or
recovery. It has demonstrated high validity, reliability, and
test-retest reliability [8,31]. The reporting timeframe is
adapted to the previous 3 months. An objective assess-
ment of engagement in addressing substance misuse will
also be carried out by reviewing the clinical notes of par-
ticipants to assess whether any discussion of substance
use has occurred, as evidenced in the clinical notes of par-
ticipants from both the MI and TAU groups.
Secondary outcomes
i) Motivation to change Readiness to change alcohol
and drug use is assessed by using the Stages Of Change
Readiness And Treatment Eagerness Scale (SOCRATES).
The measure consists of 19items that assess current readi-
ness for change. The three factors derived from the scale
are Recognition of substance use as being problematic,
Ambivalence, and Taking Steps toward change. It has been
widely used and has demonstrated good validity and reli-
ability [32].
The Importance-Confidence Ruler is a global assess-
ment of level of motivation and confidence to change that
assesses two concepts that are suggested to underpin
readiness to change [33]. Participants are asked to rate on
a scale of 0 to 10 how important it is to change the use of
the specified substance and how confident they are that
they will succeed.
ii) Drug Use and Alcohol Use Drug and alcohol use
will be assessed by using a number of complementary
measures.
The Clinicians Alcohol/Drugs Use rating scales (CDUS/
CAUS) have been developed, based on DSM-IV diagnostic
criteria for substance-related disorders, and are used by
primary clinicians to classify reliably the severity of sub-
stance use among people with severe mental health prob-
lems [31]. The measure has demonstrated sensitivity and
high levels of reliability [31]. The reporting time frame is
the previous 3 months.
Quantity and pattern of drug and alcohol use is assessed
with participants by using the drug-use profile section B of
the Maudsley Addiction Profile (MAP) [34]. This addresses
the number of days each substance has been used in the
past 30 days, the average amount of use of each drug on a
using day, and the number of days of injecting drug use.
The MAP is a widely used tool that has demonstrated good
validity and high test-retest reliability [34]. Information on
the age at onset of use of each substance also is collected.
The Severity of Dependence Scale is a validated and widely
used measure for screening the severity of dependence,
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various substances. The scale consists of five items, each
rated on a 4-point Likert scale. A score over 4 constitutes
dependency. The items focus on the individual’s anxiety,
preoccupation, and control over use of the drug. It has
high reliability across a range of samples [35-37].
The Alcohol Use Disorders Identification Test (AUDIT)
is a well-established measure, developed by the World
Health Organisation [38] to assess patterns of use and the
impacts of use. It is a 10-item self-report questionnaire in-
vestigating alcohol consumption, scored from 0 to 4 for
each question, giving a maximum score of 40. Scores of 8
or more are associated with harmful or hazardous drink-
ing, and a score of 13 or more in women, and 15 or more
in men, is likely to indicate alcohol dependence. The
AUDIT questionnaire has been found to have high levels
of reliability [39].
iii) Psychological Functioning Psychological function-
ing is measured by using the Recovery Style Questionnaire
(RSQ), Insight Scale, and the Hospital Anxiety and De-
pression Scale (HADS). The RSQ is a 39-item measure de-
signed to assess two concepts of recovery; Integration and
Sealing-over. It is a self-report measure that consists of
13 subscales, which allows six recovery styles to be classi-
fied based on a continuum (sealing over; tending toward
sealing over; mixed-picture predominantly sealing over;
mixed picture predominantly integration; tending toward
integration; integration. The RSQ has demonstrated excel-
lent psychometric properties [40].
The Insight Scale (IS) is an eight-item self-report scale
that sensitively assess changes in levels of insight in
terms of perceived need for treatment, relabeling symp-
toms as problematic, and awareness of illness. It is a
widely used scale that has demonstrated good validity
and reliability [41].
The HADS is a well-established 14-item self-report
measure that has been found to assess anxiety and depres-
sion reliably. It has demonstrated excellent psychometric
properties [42,43].
The process variable that will be measured will be per-
ceived importance and confidence to change substance
use by using the Importance-confidence ruler [33].
Cost-effectiveness analysis
Principal data on costs and resource use will be collected
prospectively alongside the trial. The intervention costs
will be calculated by using information on staff grade,
training and supervision required, and overheads. The
use of services during the inpatient stay and in the com-
munity up to follow-up will be measured by using the
Client Service Receipt Inventory [44]. These data will be
combined with appropriate unit costs (NHS Reference
Costs, PSSRU data) to calculate care costs. The EQ-5D[45] is commonly used in economic evaluations to gen-
erate QALYs. Costs will be compared between the two
groups by using bootstrapping methods to take account of
expected skewness. Costs will be combined with QALYs,
and incremental cost-effectiveness ratios constructed.
Uncertainty around these will be assessed by using cost-
effectiveness planes, and further interpretation will be
aided by constructing cost-effectiveness acceptability
curves.
Acceptability and feasibility
Qualitative interviews after the 3-month follow-up point,
by using a semistructured interview, will seek to establish
satisfaction with the treatment received and perceived
processes of change, including helpful aspects of the
therapeutic process. We will aim to understand which ele-
ments of the MI were beneficial and acceptable in the care
of people with combined mental health and substance-
misuse problems. We will also interview a sample of ther-
apists in focus groups to establish acceptability of the MI
and how it differed from standard treatment. This will
complement the analysis of the quantitative data and
identify ways in which the MI may need to be adjusted
in preparation for a definitive trial. Each interview will be
recorded and transcribed.
Analysis
Sample size
A power calculation was carried out based on a previous
study [46] by using the primary outcome measure SATS.
Allocating 68 participants by a 1:1 strategy between the
treatment and control conditions (34 participants per
group) will have 90% power (1-β) to find a difference of
1 point on the SATS scale to be statistically significant,
by using a conventional two-sided α of 0.05. A 1-point
difference would be clinically important for participants
and mental health services, as it would indicate increas-
ing levels of engagement in treatment and addressing
substance misuse (for example, a shift from “Pre-engage-
ment” to “Engagement”).
Planned analyses
We describe the characteristics of included subjects cate-
gorized by randomized group. The principal analysis will
be conducted by using the intention-to-treat principle,
based on all randomized patients. The effect of treatment
will be estimated by using generalized linear modeling
with an identity link and gaussian error. The principal
analysis uses the SATS score at follow-up as the response
variable and will include the randomized group and the
baseline SATS value as a patient-level covariate. Results
will be described as a difference in mean SATS value be-
tween randomized groups with 95% confidence intervals
and corresponding P values. All available practical steps
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patient population, it is possible that we will be unable to
include data from a small number of subjects. We will ex-
plore the potential implications of missing data by using
regression-based multiple imputation techniques.
Analysis of secondary variables will be conducted by
using an analogous approach to that applied to the primary
outcome. We will conduct additional exploratory analyses
to examine the extent to which the primary outcome is af-
fected by the length of history of involvement with ser-
vices, and other relevant patient-level characteristics. We
will explore potential therapist effects in the intervention
group by using generalized random intercept models.
Costs will be compared between the two groups by using
bootstrapping methods to take into account the expected
skewness. QALY gains will be measured with the EQ-5D.
Spearman correlations will be produced to show the strength
of the relation between QALY gains and also treatment
engagement and willingness to change measures.
For the qualitative analyses, each interview will be re-
corded and transcribed, where consent is given to record;
otherwise, detailed notes will be taken. Transcripts pro-
duced will be analyzed by using grounded theory-based
methods to identify themes that will be combined to de-
velop a model to understand participants’ and therapists’
perceptions of the treatment.
Discussion
This pilot randomized trial will be the first testing of an
intervention during inpatient care of people with severe
mental health problems and comorbid substance misuse.
If successful, the trial will provide the groundwork for
confirmatory trials to evaluate a potentially feasible, cost-
effective, and easy-to-implement treatment option that
may be readily integrated into standard inpatient and
community-based care.
Trial status
Ongoing.
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